OncoMatch/Clinical Trials/NCT06012734
LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients
Is NCT06012734 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including LB-100 and Atezolizumab for metastatic microsatellite-stable colorectal cancer.
Treatment: LB-100 · Atezolizumab — This Phase Ib trial studies the side effects and best dose of LB-100 when given with atezolizumab for the treatment of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of the tumor to grow and spread. LB-100 has been shown to make anticancer drugs work better at killing cancer. LB-100 blocks a protein on the surface of cells called PP2A. Blocking this protein increases the stress signals for the tumor cells that express PP2A. Giving atezolizumab in combination with LB-100 may work better to treat metastatic colorectal cancer patients as the cancer cells that experience increased stress signals are more susceptible for the immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care
Disease progression during treatment with standard of care
Cannot have received: CD137 agonist
Prior treatment with CD137 agonists
Cannot have received: immune checkpoint blockade therapy
Prior treatment with ... immune checkpoint blockade therapies
Cannot have received: allogeneic stem cell or solid organ transplantation
Prior allogeneic stem cell or solid organ transplantation
Lab requirements
Blood counts
Absolute neutrophil count ≥1.0×10^9/L; Lymphocyte count ≥0.5×10^9/L; Platelets≥100×10^9/L; Hemoglobin ≥5.6 mmol/L; INR ≤1.5×ULN; aPTT ≤1.5×ULN
Kidney function
Estimated glomerular filtration rate ≥50 mL/min by CKD-EPI
Liver function
AST≤2.5×ULN; ALT≤2.5×ULN; AP ≤2.5×ULN; Bilirubin ≤1.5×ULN; Albumin ≥25 g/L
Adequate hematologic and end-organ function as defined by: Absolute neutrophil (segmented and bands) count ≥1.0×10^9/L; Lymphocyte count ≥0.5×10^9/L; Platelets≥100×10^9/L; Hemoglobin ≥5.6 mmol/L; AST≤2.5×ULN; ALT≤2.5×ULN; AP ≤2.5×ULN; Bilirubin ≤1.5×ULN; Estimated glomerular filtration rate ≥50 mL/min by CKD-EPI; Albumin ≥25 g/L; INR ≤1.5×ULN; aPTT ≤1.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify